PURPOSE: This study aimed to quantify the risk of gastrointestinal cancer following Hodgkin's disease treatment according to age at treatment, type of treatment, and anatomic sites. METHODS AND MATERIALS: Cases were identified from the records of 2,441 patients treated for Hodgkin's disease between 1961 and 1994. Follow-up averaged 10.9 years, representing 26,590 person-years of observation. Relative risks (RR) for gastrointestinal cancer incidence and mortality were computed by comparison with expected annualized rates for a general population matched for age, sex, and race. RESULTS: Gastrointestinal cancers developed in 25 patients. The incidence RR was 2.5 [95% confidence interval (CI), 1.5-3.5] and mortality RR was 3.8 (CI, 2.4-4.7). Sites associated with significantly increased risks included the stomach [RR 7.3 (CI, 3.4-13.8)], small intestine [RR 11.6 (CI, 1.9-38.3)], and pancreas [RR 3.5 (CI, 1.1-8.5)]. Risk was significantly elevated after combined modality therapy, RR 3.9 (CI, 2.2-5.6). The risk after radiotherapy alone was 2.0 (CI, 1.0-3.4), not a statistically significant elevation. The RR for gastrointestinal cancer was greatest after treatment at young age and decreased with advancing age. It was significantly elevated within 10 years after treatment [RR 2.0 (CI, 1.1-3.5)] and increased further after 20 years [RR 6.1 (CI, 2.5-12.7)]. Risk assessed by attained age paralleled risk according to age at treatment. Fifteen cases of gastrointestinal cancers arose within the irradiation fields. CONCLUSION: Patients treated for Hodgkin's disease are at modestly increased risk for secondary gastrointestinal cancer, especially after combined modality therapy and treatment at a young age. Risk was highest more than 20 years after treatment, but was significantly elevated within 10 years. Gastrointestinal sites with increased risk included the stomach, pancreas, and small intestine.
PURPOSE: This study aimed to quantify the risk of gastrointestinal cancer following Hodgkin's disease treatment according to age at treatment, type of treatment, and anatomic sites. METHODS AND MATERIALS: Cases were identified from the records of 2,441 patients treated for Hodgkin's disease between 1961 and 1994. Follow-up averaged 10.9 years, representing 26,590 person-years of observation. Relative risks (RR) for gastrointestinal cancer incidence and mortality were computed by comparison with expected annualized rates for a general population matched for age, sex, and race. RESULTS:Gastrointestinal cancers developed in 25 patients. The incidence RR was 2.5 [95% confidence interval (CI), 1.5-3.5] and mortality RR was 3.8 (CI, 2.4-4.7). Sites associated with significantly increased risks included the stomach [RR 7.3 (CI, 3.4-13.8)], small intestine [RR 11.6 (CI, 1.9-38.3)], and pancreas [RR 3.5 (CI, 1.1-8.5)]. Risk was significantly elevated after combined modality therapy, RR 3.9 (CI, 2.2-5.6). The risk after radiotherapy alone was 2.0 (CI, 1.0-3.4), not a statistically significant elevation. The RR for gastrointestinal cancer was greatest after treatment at young age and decreased with advancing age. It was significantly elevated within 10 years after treatment [RR 2.0 (CI, 1.1-3.5)] and increased further after 20 years [RR 6.1 (CI, 2.5-12.7)]. Risk assessed by attained age paralleled risk according to age at treatment. Fifteen cases of gastrointestinal cancers arose within the irradiation fields. CONCLUSION:Patients treated for Hodgkin's disease are at modestly increased risk for secondary gastrointestinal cancer, especially after combined modality therapy and treatment at a young age. Risk was highest more than 20 years after treatment, but was significantly elevated within 10 years. Gastrointestinal sites with increased risk included the stomach, pancreas, and small intestine.
Authors: G M Dores; R E Curtis; F E van Leeuwen; M Stovall; P Hall; C F Lynch; S A Smith; R E Weathers; H H Storm; D C Hodgson; R A Kleinerman; H Joensuu; T B Johannesen; M Andersson; E J Holowaty; M Kaijser; E Pukkala; L Vaalavirta; S D Fossa; F Langmark; L B Travis; J F Fraumeni; B M Aleman; L M Morton; E S Gilbert Journal: Ann Oncol Date: 2014-07-25 Impact factor: 32.976
Authors: Lindsay M Morton; Graça M Dores; Rochelle E Curtis; Charles F Lynch; Marilyn Stovall; Per Hall; Ethel S Gilbert; David C Hodgson; Hans H Storm; Tom Børge Johannesen; Susan A Smith; Rita E Weathers; Michael Andersson; Sophie D Fossa; Michael Hauptmann; Eric J Holowaty; Heikki Joensuu; Magnus Kaijser; Ruth A Kleinerman; Frøydis Langmark; Eero Pukkala; Leila Vaalavirta; Alexandra W van den Belt-Dusebout; Joseph F Fraumeni; Lois B Travis; Berthe M Aleman; Flora E van Leeuwen Journal: J Clin Oncol Date: 2013-08-26 Impact factor: 44.544
Authors: Lamia Boulaâmane; El Mehdi Tazi; Meryem Glaoui; Ghizlane Raiss; Issam Lalya; Saber Boutayeb; Hind M'rabti; Hassan Errihani Journal: Pan Afr Med J Date: 2011-07-06
Authors: M Hauptmann; S D Fossa; M Stovall; F E van Leeuwen; T B Johannesen; P Rajaraman; E S Gilbert; S A Smith; R E Weathers; B M P Aleman; M Andersson; R E Curtis; G M Dores; J F Fraumeni; P Hall; E J Holowaty; H Joensuu; M Kaijser; R A Kleinerman; F Langmark; C F Lynch; E Pukkala; H H Storm; L Vaalavirta; A W van den Belt-Dusebout; L B Travis; L M Morton Journal: Br J Cancer Date: 2014-11-04 Impact factor: 7.640